Publications by authors named "Mikhail Shtivelband"

13Publications

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

J Clin Oncol 2015 Feb 5;33(5):433-41. Epub 2015 Jan 5.

Suresh S. Ramalingam and Taofeek K. Owonikoko, Winship Cancer Institute of Emory University, Atlanta, GA; Mikhail Shtivelband, Ironwood Cancer and Research Centers, Chandler, AZ; Ross A. Soo, National University Cancer Institute, National University Health System, Singapore, Singapore; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre; José G.M. Segalla, Hospital Amaral Carvalho, Jau; Jose R. Pereira, Instituto Brasileiro de Cancerologia Toracica, Sao Paulo, Brazil; Anatoly Makhson, Moscow City Oncology Hospital No. 62; Vera A. Gorbunova, N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Kenneth B. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia, Australia; Petr Kolman, Hospital Kyjov, Kyjov, Czech Republic; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing, MI; Chandra P. Belani, Penn State Hershey Cancer Institute, Hershey; Rita Axelrod, Thomas Jefferson University Hospital, Philadelphia, PA; Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, and Dawn M. Carlson, AbbVie, North Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478045PMC
February 2015

Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.

Breast 2013 Aug 14;22(4):405-10. Epub 2013 Mar 14.

Ironwood Cancer & Research Centers, 695 South Dobson Road, Chandler, AZ 85224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.02.003DOI Listing
August 2013

Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.

Clin Adv Hematol Oncol 2009 Jul;7(7):473-5

Arizona Cancer Center, University of Arizona, Tucson, AZ 85719, USA.

View Article

Download full-text PDF

Source
July 2009

Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate.

J Biol Chem 2005 May 28;280(18):18411-7. Epub 2005 Feb 28.

Vascular Biology Research Center and Division of Hematology, Brown Foundation Institute of Molecular Medicine and Medical School, The University of Texas Health Science Center and Texas Heart Institute, Houston, Texas 77030-1503, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M410017200DOI Listing
May 2005

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.

J Invest Dermatol 2004 Feb;122(2):400-5

Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.0022-202X.2004.22231.xDOI Listing
February 2004

A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo.

Clin Cancer Res 2003 Dec;9(17):6560-6

Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/9/17/6560.full
Web Search
December 2003

Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts.

FASEB J 2002 Aug 7;16(10):1286-8. Epub 2002 Jun 7.

Vascular Biology Research Center, Institute of Molecular Medicine, and Division of Hematology, University of Texas-Houston Medical School, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.01-0844fjeDOI Listing
August 2002